2021 Team
Oncobiome
Breast cancer is the most common cancer among women. Early diagnosis is vital for curative treatment. Despite nationwide screening programs only 50% of the risk population participate in the available mammography and ultrasound screening procedures. Furthermore, the identification of genetic risk populations not established. Currently available screening procedures require the acquisition of expensive instrumentation. We are developing a point-of- care device that can detect the presence of breast cancer from stool. Our invention would provide a more cost-effective and versatile method for the early detection of breast cancer. The societal impact of our invention and development is the early diagnosis of breast cancer and potentially identification of risk populations. It is likely that the part of the population currently not participating in screening programs would apply this device as it overcomes most difficulties (e.g. pain or scheduling) associated with the current state-of-the-art methodology. Overall, these advantages culminate in gain in life expectancy and the rate of successful tumor excision.
Team Lead
Peter Bay
Affiliation
University of Debrecen
Lead Mentors
Peter Bryant
Jose Estabil
Jessica Tytell
Kickoff Materials
Kickoff presentation
•
Kickoff Comments Form Responses
Question Burst
Impact Statement
Review Materials
Oncobiome Presentation Worksheet
Oncobiome Oral presentation
